TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Up 70.4% in August

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was the target of a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 20,535 shares, an increase of 70.4% from the July 30th total of 12,050 shares. Based on an average daily volume of 3,313 shares, the short-interest ratio is presently 6.2 days.

TriSalus Life Sciences Trading Down 0.9%

Shares of NASDAQ:TLSIW traded down $0.01 during midday trading on Monday, reaching $0.89. The company had a trading volume of 384 shares, compared to its average volume of 5,208. The company has a fifty day simple moving average of $0.85 and a two-hundred day simple moving average of $0.96. TriSalus Life Sciences has a 1-year low of $0.44 and a 1-year high of $2.19.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Aristeia Capital L.L.C. acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $43,000. Fort Baker Capital Management LP purchased a new position in TriSalus Life Sciences during the 4th quarter worth approximately $44,000. Citadel Advisors LLC grew its position in TriSalus Life Sciences by 439.0% during the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock worth $199,000 after purchasing an additional 103,336 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in TriSalus Life Sciences during the 4th quarter valued at $1,374,000.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.